Literature DB >> 16167050

Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.

Anthony W Tolcher1.   

Abstract

This review article focuses on the intrinsic (mitochondrial) pathway of apoptosis, the function of the Bcl-2 protein family that regulates this pathway, the background of the antisense oligonucleotide oblimersen, which targets Bcl-2 protein synthesis, and the implications for this agent in hematologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16167050

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  5 in total

1.  Targeting Bcl-2-mediated cell death as a novel therapy in pancreatic cancer.

Authors:  Diego J Muilenburg; Jodi M Coates; Subbulakshmi Virudachalam; Richard J Bold
Journal:  J Surg Res       Date:  2010-03-12       Impact factor: 2.192

Review 2.  Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?

Authors:  Elizabeth R Rayburn; Ruiwen Zhang
Journal:  Drug Discov Today       Date:  2008-05-03       Impact factor: 7.851

Review 3.  Death receptors as targets in cancer.

Authors:  O Micheau; S Shirley; F Dufour
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

4.  G3139 (Genasense) in patients with advanced merkel cell carcinoma.

Authors:  Manisha H Shah; Kimberly A Varker; Minden Collamore; James A Zwiebel; Daniel Coit; David Kelsen; Ki Y Chung
Journal:  Am J Clin Oncol       Date:  2009-04       Impact factor: 2.339

Review 5.  Apoptosis pathways and their therapeutic exploitation in pancreatic cancer.

Authors:  Simone Fulda
Journal:  J Cell Mol Med       Date:  2009-03-27       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.